Summary basis of decision for Aloxi

Health Canada has issued a Notice of Compliance to Eisai Limited for the drug product, Aloxi. Two dosage forms of Aloxi, the Aloxi injection 0.05 mg/mL, and the Aloxi capsules 0.5 mg were recommended for authorization. Aloxi contains the medicinal ingredient palonosetron hydrochloride which is a 5-HT3 receptor antagonist used to prevent nausea and vomiting associated with chemotherapy. Read more here.